Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 241 results
Filters: Author is Zheng, Lu  [Clear All Filters]
Found 241 results.

Adult

McMahon DK, Zheng L, Hitti J, et al. "Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV." Clin. Infect. Dis.. 2013;56(7):1044-51.
Macatangay BJC, Zheng L, Rinaldo CR, et al. "Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181." Clin. Vaccine Immunol.. 2010;17(9):1452-9.
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Taiwo B, Matining RM, Zheng L, et al. "Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy." J. Antimicrob. Chemother.. 2013;68(8):1857-61.
Jacobson JM, Zheng L, Wilson CC, et al. "The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection." J. Acquir. Immune Defic. Syndr.. 2016;71(2):163-71.
Zheng L, Taiwo B, Gandhi RT, et al. "Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;67(2):153-60.
Zheng L, Bosch RJ, Chan ES, et al. "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy." Antivir. Ther. (Lond.). 2013;18(1):39-43.
Jacobson JM, Wang H, Bordi R, et al. "A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;66(4):399-406.
Smith K, Zheng L, Bosch R, et al. "Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174." AIDS Res. Hum. Retroviruses. 2010;26(4):425-32.
Iii HLTwigg, Weiden M, Valentine F, et al. "Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects." J. Infect. Dis.. 2008;197(1):109-16.

Anti-HIV Agents

McMahon DK, Zheng L, Hitti J, et al. "Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV." Clin. Infect. Dis.. 2013;56(7):1044-51.
Jacobson JM, Wang H, Bordi R, et al. "A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;66(4):399-406.
Gandhi RT, Zheng L, Bosch RJ, et al. "The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial." PLoS Med.. 2010;7(8).
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Li JZ, Chapman B, Charlebois P, et al. "Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy." PLoS ONE. 2014;9(3):e90485.
Taiwo B, Matining RM, Zheng L, et al. "Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy." J. Antimicrob. Chemother.. 2013;68(8):1857-61.
Zheng L, Bosch RJ, Chan ES, et al. "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy." Antivir. Ther. (Lond.). 2013;18(1):39-43.
Gandhi RT, Coombs RW, Chan ES, et al. "No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;59(3):229-35.
Macatangay BJC, Zheng L, Rinaldo CR, et al. "Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181." Clin. Vaccine Immunol.. 2010;17(9):1452-9.

Pages